Hemlibra 30mg/1ml Injektionslösung Svizzera - Ġermaniż - Swissmedic (Swiss Agency for Therapeutic Products)

hemlibra 30mg/1ml injektionslösung

roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 30 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 1 ml. - hämophilie a - biotechnologika

Hemlibra 60mg/0.4ml Injektionslösung Svizzera - Ġermaniż - Swissmedic (Swiss Agency for Therapeutic Products)

hemlibra 60mg/0.4ml injektionslösung

roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 60 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.4 ml. - hämophilie a - biotechnologika

Hemlibra 105mg/0.7ml Injektionslösung Svizzera - Ġermaniż - Swissmedic (Swiss Agency for Therapeutic Products)

hemlibra 105mg/0.7ml injektionslösung

roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 105 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.7 ml. - hämophilie a - biotechnologika

Hemlibra 150mg/1ml Injektionslösung Svizzera - Ġermaniż - Swissmedic (Swiss Agency for Therapeutic Products)

hemlibra 150mg/1ml injektionslösung

roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 150 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 1 ml. - hämophilie a - biotechnologika

Hemlibra Unjoni Ewropea - Ġermaniż - EMA (European Medicines Agency)

hemlibra

roche registration limited - emicizumab - hämophilie a - antihämorrhagika - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra kann verwendet werden in allen altersgruppen.

Tecfidera Unjoni Ewropea - Ġermaniż - EMA (European Medicines Agency)

tecfidera

biogen netherlands b.v. - dimethylfumarat - multiple sklerose - immunsuppressiva - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).